TP53 and neoplasm: In these models, inhibition of POLR2A by α-amanitin or specific siRNA markedly reduced proliferation and tumor growth in POLR2Aloss models, independently of p53 status, suggesting a p53-independent therapeutic mechanism (Liu et al., 2015).